跳至主要内容
临床试验/RPCEC00000195
RPCEC00000195尚未招募3 期

EFFICACY OF VITAMIN E ON THE PREVENTION OF PERIPHERAL NEUROPATHY INDUCED BY CHEMOTHERAPY WITH CISPLATIN AND OXALIPLATIN - CIN-Vit E

Drug Research and Development Center CIDEM)0 个研究点目标入组 200 人开始时间: 2015年5月12日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Prevention

入排标准

年龄范围
19 years 至 70 years(—)
性别
All

入选标准

  • 1. Patients with lung, breast, gastrointestinal or head and neck neoplasia, tributary of treatment with cisplatin or oxaliplatin.
  • 2. Patients without clinical or electrophysiological diagnosis of peripheral neuropathy at the time of entry.
  • 3. Subjects of both gender, ranged between 19 and 70 years (both inclusive).
  • 4. Patient’s written, informed consent.

排除标准

  • 1. Antecedents or clinical evidence of the following pathologies: Some previous type of peripheral neuropathy, family story of any type of inherited-familiar neuropathy.
  • 2. Patients who have received prior chemotherapy.
  • 3. Patients who have received drugs that can produce peripheral nerve damage.
  • 4. Severe acute diseases at the time of entry.
  • 5. Diabetes Mellitus
  • 6. Patients receiving treatment with Amifostine, acetyl L carnitine, Glutanine, erythropoietin and infusions of Ca and Mg.
  • 7. Hypersensitivity to the active substance (Vitamin E) or some of the inactive substances that are present in the formulation.
  • 8. Concurrent participation in another clinical trial.

研究者

发起方
Drug Research and Development Center CIDEM)

相似试验